Back
Speaker illustration

Doctor Giacomo Ruotolo

Indianapolis (United States of America)

Member of:

European Society of Cardiology

Dr. Giacomo Ruotolo has dedicated his scientific career to lipoprotein metabolism and prevention of ASCVD. He received his MD, board certification in Diabetes and Metabolic Diseases, and PhD in Clinical Pathophysiology in Italy. He has trained in the States with Barbara Howard and Virgil Brown at NIH and MedStar Research Institute, and in Sweden with Anders Hamsten at Karolinska Institute. Dr. Ruotolo has been the Head of the Lipid Clinic, and Lipoprotein Research Unit at San Raffaele Institute in Milan, and the Scientific Director of Penn Medical Lab at MedStar Research Institute. He is member of the Editorial Board of Journal of Clinical Lipidology, and co-organizer of the Annual ATVB HDL Workshop. He is Fellow of American Heart Association (FAHA), European Society of Cardiology (FESC) and National Lipid Association (FNLA). Before joining Eli Lilly & Company in January 2012 as Medical Fellow, Giacomo was the ASCVD Early Clinical Development Leader at AstraZeneca in Sweden.

Presentations

Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels

Event: ESC Congress 2024

Topic: Drug therapy

Session: Lipids as cardiovascular risk factors and treatment options

Access
Thumbnail

Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes

Event: ESC Congress 2020

Topic: Metabolic Syndrome, Insulin, Insulin Resistance

Session: Risk Factors and Prevention ePosters

Access
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources